Ignite Creation Date:
2025-12-24 @ 5:03 PM
Ignite Modification Date:
2026-03-29 @ 3:59 PM
Study NCT ID:
NCT00949650
Status:
COMPLETED
Last Update Posted:
2018-04-06
First Post:
2009-07-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Sponsor:
Boehringer Ingelheim
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
1200.32
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None